Genmab A/S (OTCMKTS:GNMSF) Stock Price Crosses Above 50 Day Moving Average - Here's Why

Key Points

• Genmab A/S shares surpassed their fifty-day moving average of $229.39, trading as high as $277.60 during the session.
• The company reported earnings of $5.42 per share for the last quarter, exceeding estimates by $1.43, with a net margin of 37.53%.
• Genmab A/S has a market capitalization of $18.34 billion and continues to develop innovative antibody therapeutics for cancer treatment.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price passed above its fifty day moving average during trading on Wednesday . The stock has a fifty day moving average of $229.39 and traded as high as $277.60. Genmab A/S shares last traded at $277.60, with a volume of 10 shares trading hands.

Genmab A/S Price Performance

The business's 50-day simple moving average is $234.55 and its two-hundred day simple moving average is $214.62. The stock has a market cap of $18.83 billion, a price-to-earnings ratio of 14.31 and a beta of 0.90.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last released its quarterly earnings results on Thursday, August 7th. The company reported $5.42 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million during the quarter, compared to the consensus estimate of $949.06 million.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.